证券之星消息，11月14日，医疗健康（980016）指数报收于6572.66点，跌0.65%，成交233.97亿元，换 手率0.87%。当日该指数成份股中，上涨的有16家，甘李药业以2.0%的涨幅领涨，下跌的有33家，奕瑞 科技以3.74%的跌幅领跌。 | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603087 | 甘李药业 | 6297.79万 | 6.61% | -2315.28万 | -2.43% | -3982.51万 | -4.18% | | 002422 科伦药业 | | 5081.71万 | 12.92% | -2049.58万 | -5.21% | -3032.13万 | -7.71% | | 000661 | 长春高新 | 4881.38万 | 4.29% | 482.59万 | 4 0.42% | -5363.96万 | -4.71% | | 600535 | 天土力 | 2233.34万 | ...

11月14日，天士力盘中上涨2.06%，截至13:24，报15.86元/股，成交2.32亿元，换手率0.99%，总市值 236.94亿元。 资金流向方面，主力资金净流入719.20万元，特大单买入1224.57万元，占比5.27%，卖出1069.18万元， 占比4.60%；大单买入6499.90万元，占比27.99%，卖出5936.09万元，占比25.56%。 截至9月30日，天士力股东户数8.13万，较上期增加34.45%；人均流通股18383股，较上期减少25.62%。 2025年1月-9月，天士力实现营业收入63.11亿元，同比减少2.35%；归母净利润9.84亿元，同比增长 16.88%。 分红方面，天士力A股上市后累计派现80.53亿元。近三年，累计派现20.92亿元。 机构持仓方面，截止2025年9月30日，天士力十大流通股东中，香港中央结算有限公司位居第四大流通 股东，持股4710.82万股，相比上期增加1193.00万股。南方中证500ETF（510500）位居第六大流通股 东，持股1096.18万股，相比上期减少11.24万股。创新药（159992）位居第八大流通股东，持股738.23 万股 ...

国产创新药书写"价值医疗"新篇 根据《中国卒中学会急性缺血性卒中再灌注治疗指南2024》，我国每年约有300万卒中新发病例，其中缺血性卒中约占80%。 目前我国缺血性脑卒中发病率和死亡率仍呈现上升趋势，卒中已成为国内成人致死、致残的首位病因，也是医保支付的重要疾 病，带来巨大的社会负担。 但卒中防控仍存三大痛点——公众认知不足、防治体系需完善、基层能力薄弱。早期识别率不足三成，急救黄金时间常被浪 费，溶栓取栓技术普及率低，健康素养亟待提升。 普佑克作为我国自主研发的第三代溶栓药物，精准破解了这一行业痛点。其通过独特的纤溶酶原靶向激活机制，在实现高效血 管再通的同时显著降低出血风险。 近期，国际顶级医疗期刊《JAMA》和《柳叶刀-神经病学》相继发表研究成果，显示接受重组人尿激酶原(普佑克)溶栓患者，较 对照组在效果一致的前提下，呈现出更低的脑出血发生率(PROST-2研究)，且7天内溶栓相关的大出血和全身系统性出血事件发 生率也都显著低于对照组。 天士力研发中心负责人指出，作为新一代溶栓药物，普佑克的核心优势源于独特的分子结构与作用机制。普佑克的活性成分为 重组人尿激酶原，功能及安全性与人体天然分泌的尿激酶原最 ...

2025 年 11 月 10 日 行业研究 医疗器械和医疗服务板块收入表现靓丽，化学制剂板块净利润同比增长 ——医药生物行业跨市场周报（20251109） 要点 行情回顾：上周，医药生物指数下跌 2.40%，跑输沪深 300 指数 3.22pp，在 31 个子行业中排名第 29。港股恒生医疗健康指数上周收跌 2.62%，跑输恒生国企 指数 3.7pp。 本周观点：医疗器械和医疗服务板块收入表现靓丽，化学制剂板块净利润同比增 长。 25 年前三季度医药生物板块实现收入 18257.4 亿元（YOY-1.97%），实现归母 净 利 润 1396.6 亿 元 （ YOY-1.59% ） ； 单 三 季 度 实 现 收 入 5985.4 亿 元 （YOY+0.78%），实现归母净利润 405.1 亿元（YOY+7.67%）。从毛利表现来 看，25 年前三季度医药板块实现销售毛利润 5734.5 亿元（YOY-6.1%），对应 整体毛利率为 31.4%（YOY-1.4pct）。从各医药申万二级行业表现来看，25Q3 各板块继续分化，医疗器械和医疗服务板块收入表现靓丽，化学制剂板块净利润 继续同比增长，其他细分子板块表现 ...

Core Insights - Tianjin Shili Group announced the launch of a health and wellness tourism strategy upgrade during the "2026 National Taiwan Quality Commitment Conference and National Taiwan Digital Collection Wine Sealing Ceremony" held in Renhuai, Guizhou [1] Strategic Initiatives - The company outlined a health and wellness tourism strategy path led by "wine and tourism integration," emphasizing the dual commitment to traditional craftsmanship and digital transformation [3] - The strategy includes the promotion of a "tea and tourism integration" plan through its subsidiary, Di Bo Er Pu'er Tea, focusing on hotels, resorts, and comprehensive tourism complexes [3] Ecosystem Development - The strategic initiative will leverage a partnership with Guizhou Tianyue Tourism Group, which has been operational since April 2017 and has received over 500,000 tourists annually, ranking among the top 20 travel agency brands in China by 2025 [3] - This marks a significant transformation for Tianjin Shili Group from a health product manufacturer to an integrated operation platform combining "products + services + scenarios" [3]

Core Insights - The company is launching a strategic upgrade in the health and wellness tourism sector, appointing Wang Qunfu as CEO of the new division [1][5] - The strategy emphasizes the integration of traditional liquor production with digital upgrades and immersive cultural experiences [3][5] Strategic Initiatives - The health and wellness tourism strategy is centered around "liquor and tourism integration," aiming to create a seamless value chain from production to experiential tourism [3] - The company plans to enhance its offerings by developing immersive cultural experiences related to its liquor products [3] Ecological Layout - The company will also promote a "tea and tourism integration" plan through its subsidiary, focusing on hotels, resorts, and comprehensive tourism complexes [4] - A strategic partnership with Guizhou Tianyue Tourism Group will leverage their resources to enhance channel integration and cultural exploration [4] Transformation Goals - The strategic upgrade signifies a shift from being a health product manufacturer to an integrated platform combining products, services, and experiences [5] - The company aims to extend traditional health consumer products into a composite ecosystem that merges tourism experiences with cultural dissemination [5]

Core Viewpoint - Tian Shi Li (600535.SH) reported a decline in third-quarter revenue but an increase in net profit attributable to shareholders, indicating mixed financial performance for the company in 2025 [1][2]. Financial Performance Summary - The company's third-quarter revenue was 2.022 billion yuan, a year-on-year decrease of 3.27% [1][2]. - Net profit attributable to shareholders was 210 million yuan, reflecting a year-on-year increase of 16.56% [1][2]. - Net profit excluding non-recurring gains and losses was 189 million yuan, showing a year-on-year decline of 23.64% [1][2]. - For the first three quarters of 2025, total revenue was 6.311 billion yuan, down 2.35% year-on-year [2]. - Net profit attributable to shareholders for the first three quarters was 984 million yuan, up 16.88% year-on-year [2]. - Net profit excluding non-recurring gains and losses for the first three quarters was 829 million yuan, down 15.59% year-on-year [2]. - The net cash flow from operating activities was 873 million yuan, a decrease of 26.67% year-on-year [2]. Shareholding Structure Changes - Tian Shi Li's controlling shareholder changed from Tian Shi Li Biological Pharmaceutical Industry Group to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. after a share transfer [3][4]. - Following the transfer, Tian Shi Li Group and its concerted parties held 261,452,489 shares, representing 17.50% of the total share capital [3][4]. - China Resources Sanjiu directly holds 418,306,002 shares, accounting for 28% of the total share capital [3][4]. - The total transfer price for the shares was approximately 6.21 billion yuan [4].

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a decline in revenue for Q3 2025, while net profit showed growth, indicating mixed financial performance [1] Financial Performance - In Q3 2025, the company achieved revenue of 2.022 billion yuan, a year-on-year decrease of 3.27% [1] - The net profit attributable to shareholders for Q3 2025 was 210 million yuan, reflecting a year-on-year increase of 16.56% [1] - For the first three quarters of 2025, total revenue reached 6.311 billion yuan, down 2.35% compared to the same period last year [1] - The net profit attributable to shareholders for the first three quarters was 984 million yuan, which is a year-on-year increase of 16.88% [1] Revenue Breakdown - The revenue from the pharmaceutical manufacturing segment decreased by 0.47% year-on-year [1] - The revenue from the pharmaceutical commerce segment saw a significant decline of 16.70% year-on-year [1]

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.31% on October 27, with Zhenbaodao leading the drop [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 23.90, up 3.46% [1] - ST Xiangxue (300147) at 10.25, up 2.60% [1] - Jiuzi Tang (000989) at 10.02, up 2.14% [1] - Conversely, Zhenbaodao (603567) saw a significant decline of 6.23%, closing at 11.13 [2] - Other notable decliners included: - Taiji Group (600129) down 3.21% [2] - Kunming Pharmaceutical Group (600422) down 2.21% [2] Capital Flow - The traditional medicine sector experienced a net outflow of 344 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [2] - The sector's overall capital flow indicated a mixed sentiment, with speculative funds showing a net inflow of 163 million yuan [2] Individual Stock Capital Flow - Key stocks with significant capital flow included: - Jilin Aodong (000623) with a net inflow of 81.97 million yuan from institutional investors [3] - Yunnan Baiyao (000538) with a net inflow of 62.26 million yuan [3] - Jiuzi Tang (000989) with a net inflow of 26.22 million yuan [3] - Notable outflows were observed in: - Jilin Aodong with a retail net outflow of 72.25 million yuan [3] - Yunnan Baiyao with a retail net outflow of 67.54 million yuan [3]

Core Viewpoint - Zhejiang Merchants Securities report indicates that Tianjin Tasly Pharmaceutical achieved a net profit attributable to shareholders of 984 million yuan in the first three quarters, representing a year-on-year increase of 16.88% [1] - In Q3 alone, the net profit attributable to shareholders was 210 million yuan, also reflecting a year-on-year growth of 16.56% [1] - The performance aligns with expectations, and there is optimism regarding the empowerment from Sanjiu [1] Financial Performance - The net profit for the first three quarters reached 984 million yuan, marking a 16.88% increase compared to the previous year [1] - The Q3 net profit was recorded at 210 million yuan, showing a 16.56% year-on-year growth [1]